CAS 159519-65-0 Enfuvirtide Acetate (T-20)

Enfuvirtide Acetate CAS No.: 159519-65-0
Sequence: Ac-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2
Enfuvirtide is an anti-HIV-1 fusion inhibitor peptide used in combination therapy for the treatment of HIV-1/AIDS. It works by disrupting the HIV-1 molecular machinery at the final stage of fusion with the target cell, preventing uninfected cells from becoming infected.

Related Products 

Company Profile 

   Founded in 2011, Harbin Jixianglong Biotech Co., Ltd. is a is a professional high-tech company specializing in R&D and production of polypeptide pharmaceuticals. Our advanced industry chain occupied in R&D, approbation and industrialization of peptides API and preparation.
   Jixianglong has peptide drug production workshop and pilot workshop for personalized cancer neoantigen peptide vaccine which approved by GMP standard. More than 300 sets advanced instruments for production and testing, such as Solid phase synthesizer, Preparative liquid chromatograph, Freeze dryer, High performance liquid chromatograph etc.
Main Products:
10 items completed polypeptide API declared:
Eptifibatide, Somatostatin, Terlipressin Acetate, Thymalfasin, Atosiban Acetate, Carbetocin, Oxytocin, Ganirelix Acetate, Octreotide Acetate, Cetrorelix Acetate.
N items as researching reserve series:
Teriparatide, Bivalirudin, Liraglutide, Nesiritide, Abaloparatide, Semaglutide, Personalized cancer neoantigen peptide vaccine,  Peptide drug conjugate (PDC).